04:01 PM EDT, 07/18/2024 (MT Newswires) -- Dr. Reddy's Laboratories (RDY) on Thursday disclosed plans to commercialize and sell Takeda Pharmaceutical's ( TAK ) vonoprazan tablets to treat gastroesophageal reflux disease, peptic and duodenal ulcers and similar disorders to customers in India.

Under the terms of the non-exclusive patent licensing agreement, Dr. Reddy's plans to market the orally active potassium competitive acid blocker in either 10- or 20-milligram tablet strengths under the Vono trademark.

Financial terms of the agreement were not disclosed.

Price: 79.03, Change: -0.05, Percent Change: -0.06